Development Funding Alize Pharma Closes Development Funding With € 3.3 Million
French pharmaceutical consortium Alize Pharma has raised € 3.3 million funds for the clinical development of its UAG (UnAcylated Ghrelin) analog for the treatment of the Prader Willi syndrome and type II diabetes. With this money, Phase I clinical trials can be started for the company's AZP-531, an UAG (UnAcylated Ghrelin) analog, spekers explained.
Lyon/France – Now, Alize Pharma, a group of companies developing drugs for the treatment of metabolic diseases and cancer, will start a first (Phase I) clinical trial of AZP-531 in healthy volunteers in 2013. A Phase Ib and Phase II trials in patients with type II diabetes as well as in patients suffering from the Prader Willi syndrome is planned after the succesful completion of the initial trials.
Preclinical and clinical data suggest that UAG and its analogs have therapeutic potential in the targeted indications, by reducing acylated ghrelin blood levels, improving glycemic control and insulin sensitivity, and improving additional cardiovascular risk factors, the company explained.
Shareholders Participate in Development Fundin
Most of the company’s main shareholders also participated in the funding round, namely Sham, Octalfa, Cema and Thierry Abribat. Since its creation, the company has now raised a total of EUR 8.3 million. “We are grateful to our shareholders for their renewed confidence and support and are very enthusiastic to initiate the clinical development of our UAG analog,” said Thierry Abribat, president & CEO of Alize Pharma. “This development program is extremely important, since it will address significant unmet clinical needs in type II diabetes and the Prader Willi syndrome. In line with our business model, the results obtained from the first clinical trials will help us select a pharmaceutical partner capable of developing and commercializing the product under a licensing agreement.”
Development Strategy Pleases Backers
During the development of the new treatments, important R&D milestones were already reached and first strategic partnerships underway, Alize Phram said. Also the shareholder express their confidence:
“As a historic shareholder in Alize Pharma, we are very pleased to support its development strategy,” said Gilles Alberici, president of Octalfa. “The quality of the team and the research programs are outstanding and we strongly believe in the company’s business model, as demonstrated by the success of the ASPAREC(R) program.”
Small and medium enterprises are often driving forces of innovation and competition – The EU wants tounleash their potentials for the future European bio–economy by establishing Biochem, a project that supports SMEs with networking agencies, venture and public funding and programme consultancies in seven Member States.
New Unacylated Ghrelin Analog for Diabetes Treatment
AZP-531, the first unacylated ghrelin analog., is the result of a UAG development programme started in 2007: This 8-amino acid peptide is stable and its pharmacokinetic properties make it suitable for pharmaceutical development. AZP-531 will be the first unacylated ghrelin analog to enter regulatory development, company speakers belive.
“The mechanism of action of AZP-531 may lead to improved glycemia control in type II diabetes and also to positive effects on other cardiovascular risk factors, such as obesity, dyslipidemia and vascular complications,” explained Professor AJ van der Lely, head of the clinical endocrinology department at the Erasmus Medical Center in Rotterdam (Netherlands) and scientific advisor at Alize Pharma. “In addition, it could be used to target clinical conditions where acylated ghrelin levels are abnormally high, such as the Prader Willi syndrome, thus opening up a new treatment option for these patients.”
Portfolio of 34 Pharmaceutical Patents
Currently Alize Pharma owns a portfolio of five families of patents comprising a total of 34 patents and patent applications for the protection of UAG, its analogs, including AZP-531, and their applications. Professor AJ van der Lely and his team will present new clinical data on the effects of unacylated ghrelin in diabetic patients at the upcoming annual meeting of the Endocrine Society (ENDO 2012) that will be held in Houston from June 23 to 26, 2012.